Please assess the completion status of the following clinical trial:

Trial Title: Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with histologically- or cytologically-confirmed non-squamous non-small cell lung cancer~* Subjects who received a diagnosis of stage IIIB/IV or recurrent non-squamous non-small cell lung cancer unsuitable for radical radiation according to the UICC-TNM Classification (7th edition) with no prior systemic anticancer therapy~* Subjects with at least one measurable lesion by radiographic tumor assessments per RECIST 1.1 criteria~* Subjects who are able to provide tumor tissue specimens.~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1~Exclusion Criteria:~* Subjects with known EGFR mutations, including deletions in exon 19 and exon 21 (L858R) substitution mutations.~* Subjects with known ALK translocations.~* Complication or history of severe hypersensitivity reactions to antibody products or platinum-containing compounds~* Subjects with autoimmune disease or known chronic or recurrent autoimmune disease.~* Subjects with multiple cancer.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ONO-4538 group (Type: EXPERIMENTAL): ONO-4538: 360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.~Chemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
- Placebo group (Type: PLACEBO_COMPARATOR): Placebo: Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.~Chemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.

Based on this trial design, predict the completion outcome and termination type (if applicable).